17,261 trials
Corona Virus Infection
Primary: Percentage of Participants With Non-invasive Ventilation, Mechanical Ventilation or Death at Day 14 -- Severe COVID Population (WHO Clinical Progression Scale =5 at…
Type 1 Diabetes
Primary: Change in C-peptide Measurement as Reflection of Insulin Secretion at 6 Months — -0.07; -0.07 nmol/L*120 min
Dermatitis, Atopic
Primary: Percentage of Participants With a Positive Serum Immunoglobulin G (IgG) Response (>= 4-Fold Increase or >= 0.2 IU/mL in Anti-Tetanus IgG Concentrations) to Tetanus…
Myelodysplastic Syndromes · Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma
Primary: Phase II: Estimated Percent of Participants Who Experienced Severe Chronic Graft Versus Host Disease (GVHD) — 6.0 Estimated percent of participants
Dry Eye Disease
Primary: University of North Carolina Dry Eye Management Scale (UNC DEMS) Responder Analysis — 53.2; 60.0; 65.2 percentage of responders — p=0.2933
Pulmonary Arterial Hypertension
Primary: Percent Change From Baseline of Pulmonary Vascular Resistance (PVR) at Week 24 — 63.083; 64.219; 5.813 percent — p=0.0208
Metastatic Esophageal Carcinoma · Metastatic Gastric Carcinoma · Metastatic Gastroesophageal Junction Adenocarcinoma
Primary: Dose Limiting Toxicity and Maximum Tolerated Dose of Olaparib (Phase I) — 0; 1 Participants
Plasma Cell Myeloma
Primary: Proportion of Patients Who Achieve a Confirmed Complete Response (CR) — 0.32; 0.30 proportion of participants
Covid19
Primary: Respiratory Failure-free Survival in Participants With Moderate-severe COVID-19 Who Are Treated With ATI-450 — 50; 60 percentage of total patients
Autism Spectrum Disorder · Developmental Disability · Aggression
Primary: Aberrant Behavior Checklist--Community (ABC-C) Irritability Subscale Scores — 14.0; 18.50 score on a scale — p=0.12
Atypical Hyperplasia · Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia · Endometrial Carcinoma
Primary: Change in Tumor Proliferation — -0.17 percent (represented by mean) of cells
Brain Tumor · Low Grade Glioma · Astrocytoma
Primary: Endocrine Dysfunction — 14.5; 20.2 percentage of participants
RET-altered Non Small Cell Lung Cancer · Medullary Thyroid Cancer · RET-altered Papillary Thyroid Cancer
Primary: Phase 1 : Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Pralsetinib — 400; 400 mg
Acute Myeloid Leukemia · AML
Primary: Safety and Tolerability of Experimental Dose of Palbociclibin Combination With CPX-351 as Measured by Number of Participants With Dose Limiting Toxicities. — 0…
Large B-cell Diffuse Lymphoma of Testis
Primary: Adverse Events Assessment — 6; 3; 3 Participants